HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

IMPACT THERAP-B

12.900

+1.28011.02%

Volume:9.54M

Turnover:119.65M

Market Cap:3.64B

PE:-9.96

High:14.000

Open:11.740

Low:10.700

Close:11.620

52wk High:47.980

52wk Low:10.310

Shares:282.46M

HK Float Shares:282.46M

Volume Ratio:6.27

T/O Rate:3.38%

Dividend:- -

Dividend Rate:- -

EPS(LYR):-1.295

ROE:--

ROA:-40.35%

PB:4.02

PE(LYR):-9.96

PS:26.37

Loading ...

Overview Company News Filings

Impact Therapeutics Proposes 10-year Share Award Scheme Capped at 5% of Issued Shares

IMPACT Therapeutics Schedules 27 July 2026 Extraordinary General Meeting; Share Transfer Books Close 22–27 July 2026

Bulletin Express

Impact Therapeutics Announces Extraordinary General Meeting

Tencent Holdings Boosts Stake in IMPACT THERAP-B with 350,000 Share Purchase at Average Price

Major Shareholder Boosts Stake in IMPACT THERAP-B with Additional 20,000 Shares

IMPACT Therapeutics boosts share capital by 2.30 % through full over-allotment option exercise

Bulletin Express

IMPACT THERAP-B Issues 6.3 Million H Shares Upon Full Exercise of Over-Allotment Option

IMPACT Therapeutics Concludes Stabilization; 6.30 Million H Shares Allotted at HK$20.10 Each

Bulletin Express

IMPACT THERAP-B Concludes Stabilization Period with Full Exercise of Over-Allotment Option

Impact Therapeutics Nets HK$120 Million From Full Exercise of IPO Overallotment Option

MT Newswires Live

IMPACT Therapeutics Raises HK$119.50 Million via Full Exercise of 15% Over-Allotment Option

Bulletin Express

IMPACT THERAP-B Fully Exercises Over-Allotment Option

Transcenta names Hansen Xu non-executive director, Jun Bao independent director

IMPACT Therapeutics Sets 25 June 2026 AGM; Shareholders to Vote on 2025 Results, Auditor Re-Appointment and Dual Mandates

Bulletin Express

IMPACT Therapeutics Sets 25 June 2026 AGM; Board Requests 20% Issuance Mandate and 10% H-Share Buy-back Authority

Bulletin Express

Impact Therapeutics announces annual shareholder meeting

IMPACT THERAP-B (07630) to Unveil Phase I/II Trial Results for IMP1734 at 2026 ASCO Annual Meeting

IMPACT Therapeutics highlights IMP1734 Phase 1/2 data at ASCO 2026; monotherapy ORR 14.3%, paclitaxel combo ORR 24.5%

Bulletin Express

Impact Therapeutics says PARP1 inhibitor IMP1734 posts 14.3% ORR in Phase 1/2 monotherapy data at ASCO 2026

Stock Track | Impact Therapeutics-B Soars 15.59% Intraday in Strong Rebound After Post-IPO Profit-Taking

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.imtigers.com/stock/07630/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"07630","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"07630\",,,,,undefined,":{"symbol":"07630","market":"HK","secType":"STK","nameCN":"IMPACT THERAP-B","latestPrice":12.9,"timestamp":1789114134171,"preClose":11.62,"halted":0,"volume":9540600,"delay":0,"changeRate":0.11015490533562833,"floatShares":282461530,"shares":282461530,"eps":-1.294715,"marketStatus":"Not Yet Opened","change":1.28,"latestTime":"09-11 16:08:54","open":11.74,"high":14,"low":10.7,"amount":119654734,"amplitude":0.283993,"askPrice":13,"askSize":1200,"bidPrice":12.9,"bidSize":27200,"shortable":0,"etf":0,"ttmEps":-1.052,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1789349400000},"marketStatusCode":0,"adr":0,"listingDate":1778601600000,"exchange":"SEHK","adjPreClose":11.62,"openAndCloseTimeList":[[1789090200000,1789099200000],[1789102800000,1789113600000]],"volumeRatio":6.265679632395429,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"07630\",,,,,undefined,":{"symbol":"07630","floatShares":282461530,"roa":"-40.35%","roe":"--","lyrEps":-1.294715,"volumeRatio":6.265679632395429,"shares":282461530,"dividePrice":0,"high":14,"amplitude":0.283993,"preClose":11.62,"low":10.7,"week52Low":10.31,"pbRate":"4.02","psRate":"26.37","week52High":47.98,"institutionHeld":0,"latestPrice":12.9,"committee":0.915493,"eps":-1.294715,"divideRate":0,"volume":9540600,"delay":0,"ttmEps":-1.052,"open":11.74,"prevYearClose":20.1,"prevWeekClose":12.9,"prevMonthClose":14.46,"prevQuarterClose":36.08,"fiveDayClose":15.59,"twentyDayClose":12.84,"sixtyDayClose":37.68},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/07630\",params:#limit:5,,,undefined,":[{"date":"2026-08-31","symbol":"07630","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1788139800000,"name":null,"time":"","dateTimestamp":1788105600000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"07630\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"07630\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0,"buy":0,"hold":1,"sell":0,"strongSell":0,"meanLabel":"HOLD","meanPercent":1,"analysts":1,"updateTime":1782230400000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/07630\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"07630","date":"2026-09-11","current":-12.262357,"percent":0.607143,"low":-34.323153,"twenty":-30.026033,"median":-14.57977,"eighty":-10.495083,"high":-8.821219,"avg":-19.114589,"sd":9.329759,"marketCap":3643753737},"quantilePoints":[{"date":"2026-05-15","current":-32.36994,"twenty":-32.973318,"median":-32.357426,"eighty":-26.127101,"marketCap":11057651805},{"date":"2026-05-22","current":-30.548005,"twenty":-32.354923,"median":-30.958502,"eighty":-28.393426,"marketCap":10411425401},{"date":"2026-05-29","current":-32.218614,"twenty":-32.294393,"median":-30.958502,"eighty":-30.148817,"marketCap":11018988687},{"date":"2026-06-05","current":-29.849738,"twenty":-32.359929,"median":-31.257987,"eighty":-30.148817,"marketCap":10223633112},{"date":"2026-06-12","current":-29.369689,"twenty":-32.33377,"median":-30.548005,"eighty":-29.705347,"marketCap":10052410732},{"date":"2026-06-18","current":-29.78235,"twenty":-32.303072,"median":-30.338658,"eighty":-29.742668,"marketCap":10218109810},{"date":"2026-06-26","current":-29.297581,"twenty":-32.241427,"median":-30.11999,"eighty":-29.607619,"marketCap":10002701008},{"date":"2026-07-03","current":-16.26247,"twenty":-32.218614,"median":-29.994357,"eighty":-29.297581,"marketCap":5556442415},{"date":"2026-07-10","current":-15.780707,"twenty":-31.493905,"median":-29.916258,"eighty":-25.475578,"marketCap":5385220035},{"date":"2026-07-17","current":-11.297625,"twenty":-31.022068,"median":-29.816044,"eighty":-15.922995,"marketCap":3869073471},{"date":"2026-07-24","current":-9.271485,"twenty":-30.958502,"median":-29.609087,"eighty":-15.602668,"marketCap":3175898995},{"date":"2026-07-31","current":-10.646015,"twenty":-30.630104,"median":-29.369689,"eighty":-13.307417,"marketCap":3653664669},{"date":"2026-08-07","current":-10.047131,"twenty":-30.493855,"median":-29.24895,"eighty":-10.58915,"marketCap":3454825776},{"date":"2026-08-14","current":-10.299125,"twenty":-30.36699,"median":-25.475578,"eighty":-10.316459,"marketCap":3545960269},{"date":"2026-08-21","current":-10.772628,"twenty":-30.33128,"median":-16.418396,"eighty":-10.292557,"marketCap":3717182649},{"date":"2026-08-28","current":-12.490535,"twenty":-30.224959,"median":-15.896725,"eighty":-10.316459,"marketCap":4310937679},{"date":"2026-09-04","current":-14.62831,"twenty":-30.072679,"median":-15.691688,"eighty":-10.353511,"marketCap":4403575252},{"date":"2026-09-11","current":-12.087934,"twenty":-30.026033,"median":-14.57977,"eighty":-10.495083,"marketCap":3643753737}],"updateTime":1789329983719},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"07630\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2650380871","title":"Impact Therapeutics Proposes 10-year Share Award Scheme Capped at 5% of Issued Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2650380871","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650380871?lang=en_us&edition=fundamental","pubTime":"2026-07-10 21:26","pubTimestamp":1783690001,"startTime":"0","endTime":"0","summary":"Impact Therapeutics proposes 10-year share award scheme capped at 5% of issued sharesImpact Therapeutics proposed a 2026 share award (existing shares) scheme, subject to shareholder approval at an ext","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260710:nNDL27ydXt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152854319","title":"IMPACT Therapeutics Schedules 27 July 2026 Extraordinary General Meeting; Share Transfer Books Close 22–27 July 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=1152854319","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1152854319?lang=en_us&edition=fundamental","pubTime":"2026-07-08 19:22","pubTimestamp":1783509734,"startTime":"0","endTime":"0","summary":"IMPACT Therapeutics, Inc. has announced that its first extraordinary general meeting (EGM) for 2026 will be held on Monday, 27 July 2026. The company’s register of members will be closed from...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649989709","title":"Impact Therapeutics Announces Extraordinary General Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2649989709","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649989709?lang=en_us&edition=fundamental","pubTime":"2026-07-08 19:13","pubTimestamp":1783509227,"startTime":"0","endTime":"0","summary":"Impact Therapeutics announces extraordinary general meetingImpact Therapeutics will hold its 2026 first extraordinary general meeting on July 27, 2026, in Hong Kong.The company will publish a circular","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260708:nNDLyLlBZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106472584","title":"Tencent Holdings Boosts Stake in IMPACT THERAP-B with 350,000 Share Purchase at Average Price","url":"https://stock-news.laohu8.com/highlight/detail?id=1106472584","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1106472584?lang=en_us&edition=fundamental","pubTime":"2026-07-06 19:43","pubTimestamp":1783338221,"startTime":"0","endTime":"0","summary":"According to the latest data from the Hong Kong Stock Exchange, Tencent Holdings Limited increased its holding in IMPACT THERAP-B (07630) on June 30. The company acquired 350,000 shares at an average...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4581","EWH","BK4585","EDZ","BK1161","BK4550","BK4504","IEMG","07630","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124994675","title":"Major Shareholder Boosts Stake in IMPACT THERAP-B with Additional 20,000 Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=1124994675","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1124994675?lang=en_us&edition=fundamental","pubTime":"2026-06-29 22:21","pubTimestamp":1782742888,"startTime":"0","endTime":"0","summary":"According to the latest data from the Hong Kong Stock Exchange, on June 24th, shareholder Shi Yi increased their holdings in IMPACT THERAP-B (07630) by 20,000 shares. The transaction was executed at...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630","EWH","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157701649","title":"IMPACT Therapeutics boosts share capital by 2.30 % through full over-allotment option exercise","url":"https://stock-news.laohu8.com/highlight/detail?id=1157701649","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1157701649?lang=en_us&edition=fundamental","pubTime":"2026-06-11 06:23","pubTimestamp":1781130203,"startTime":"0","endTime":"0","summary":"IMPACT Therapeutics, Inc. (IMPACT THERAP-B) reported that the joint global coordinators fully exercised the over-allotment option on 10 June 2026, resulting in the issuance and allotment of 6.30...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150770934","title":"IMPACT THERAP-B Issues 6.3 Million H Shares Upon Full Exercise of Over-Allotment Option","url":"https://stock-news.laohu8.com/highlight/detail?id=1150770934","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1150770934?lang=en_us&edition=fundamental","pubTime":"2026-06-11 06:16","pubTimestamp":1781129774,"startTime":"0","endTime":"0","summary":"IMPACT THERAP-B (HKEX: 07630) has announced that on June 10, 2026, it issued and allotted 6.2964 million H shares as a result of the full exercise of the over-allotment option.","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179114095","title":"IMPACT Therapeutics Concludes Stabilization; 6.30 Million H Shares Allotted at HK$20.10 Each","url":"https://stock-news.laohu8.com/highlight/detail?id=1179114095","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1179114095?lang=en_us&edition=fundamental","pubTime":"2026-06-08 17:03","pubTimestamp":1780909380,"startTime":"0","endTime":"0","summary":"IMPACT Therapeutics, Inc. (IMPACT Therapeutics) announced the completion of its post-listing stabilization period on 7 June 2026, exactly 30 days after the close of the Hong Kong Public Offering....","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132981482","title":"IMPACT THERAP-B Concludes Stabilization Period with Full Exercise of Over-Allotment Option","url":"https://stock-news.laohu8.com/highlight/detail?id=1132981482","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1132981482?lang=en_us&edition=fundamental","pubTime":"2026-06-08 16:56","pubTimestamp":1780909011,"startTime":"0","endTime":"0","summary":"The stabilization period relating to the company's global offering concluded on Sunday, June 7, 2026, which is the 30th day after the deadline for submitting Hong Kong public offering...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641172548","title":"Impact Therapeutics Nets HK$120 Million From Full Exercise of IPO Overallotment Option","url":"https://stock-news.laohu8.com/highlight/detail?id=2641172548","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641172548?lang=en_us&edition=fundamental","pubTime":"2026-06-08 09:15","pubTimestamp":1780881354,"startTime":"0","endTime":"0","summary":"Impact Therapeutics  said the overallotment option of its Hong Kong initial public offering was fully exercised on Friday, according to a same-day Hong Kong bourse filing.The Chinese biopharmaceutical company expects to raise about HK$119.5 million in additional net proceeds.The exercise involved the issue of 6.3 million additional H-shares at HK$20.10 each, representing about 15% of the total offer shares initially available under the global offering.Dealings in the overallotment shares are expected to begin on June 10, the filing said.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","BK4139","BK4007","BK4539","IPOS","07630","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199847182","title":"IMPACT Therapeutics Raises HK$119.50 Million via Full Exercise of 15% Over-Allotment Option","url":"https://stock-news.laohu8.com/highlight/detail?id=1199847182","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1199847182?lang=en_us&edition=fundamental","pubTime":"2026-06-05 21:03","pubTimestamp":1780664606,"startTime":"0","endTime":"0","summary":"IMPACT Therapeutics, Inc. announced that the overall coordinators have fully exercised the 15% over-allotment option linked to the company’s recent Hong Kong IPO. An additional 6.30 million H shares...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152339070","title":"IMPACT THERAP-B Fully Exercises Over-Allotment Option","url":"https://stock-news.laohu8.com/highlight/detail?id=1152339070","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1152339070?lang=en_us&edition=fundamental","pubTime":"2026-06-05 20:56","pubTimestamp":1780664180,"startTime":"0","endTime":"0","summary":"IMPACT THERAP-B (07630) has announced that the over-allotment option detailed in the prospectus has been fully exercised by the overall coordinators on Friday, June 5, 2026. This action, taken on...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640138154","title":"Transcenta names Hansen Xu non-executive director, Jun Bao independent director","url":"https://stock-news.laohu8.com/highlight/detail?id=2640138154","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640138154?lang=en_us&edition=fundamental","pubTime":"2026-06-04 19:19","pubTimestamp":1780571941,"startTime":"0","endTime":"0","summary":"Transcenta set to add Hansen Xu as non-executive director, pending shareholder vote at a June 30, 2026 AGM.Xu has been an investment manager since 2021, now a vice president at Liyan Enterprise Management Consulting ; previously a BCG consultant.Jun Bao to rejoin as independent non-executive director, also subject to the AGM vote; he previously served on the board from March 2021 to August 2023.Bao is chief business officer at Biotheus since 2022; previously CEO of Impact Therapeutics, with earlier business development roles at GSK and Onyx.Independent directors Kumar Srinivasan and Zhihua Zhang to step down once the appointments take effect; board committee leadership to be reshuffled.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tr","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260604:nNDL7M7ZQ1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","06628","07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123127100","title":"IMPACT Therapeutics Sets 25 June 2026 AGM; Shareholders to Vote on 2025 Results, Auditor Re-Appointment and Dual Mandates","url":"https://stock-news.laohu8.com/highlight/detail?id=1123127100","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1123127100?lang=en_us&edition=fundamental","pubTime":"2026-06-03 19:05","pubTimestamp":1780484712,"startTime":"0","endTime":"0","summary":"IMPACT Therapeutics, Inc. has circulated a proxy form ahead of its 2025 Annual General Meeting, scheduled for 10:00 a.m. on Thursday, 25 June 2026, at the Board Room, 27F, New Bund Times Square, 399...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183390771","title":"IMPACT Therapeutics Sets 25 June 2026 AGM; Board Requests 20% Issuance Mandate and 10% H-Share Buy-back Authority","url":"https://stock-news.laohu8.com/highlight/detail?id=1183390771","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1183390771?lang=en_us&edition=fundamental","pubTime":"2026-06-03 18:43","pubTimestamp":1780483434,"startTime":"0","endTime":"0","summary":"IMPACT Therapeutics, Inc. has convened its 2026 Annual General Meeting (AGM) for 10:00 a.m. on 25 June 2026 at the company’s Board Room, 27F, New Bund Times Square, 399 West Haiyang Road, Pudong...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640905626","title":"Impact Therapeutics announces annual shareholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2640905626","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640905626?lang=en_us&edition=fundamental","pubTime":"2026-06-03 18:34","pubTimestamp":1780482850,"startTime":"0","endTime":"0","summary":"Impact Therapeutics will hold its annual general meeting in Shanghai on June 25, 2026.Shareholders will vote on the 2025 board work report, the accountant’s report for 2025, and the 2025 profit distribution plan.Other items include re-appointing Ernst & Young as auditor for 2026, proposed amendments to the articles of association.Resolutions also cover a general mandate to issue shares up to 20% of shares in issue, plus a mandate to repurchase up to 10% of H shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Impact Therapeutics Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange  , on June 03, 2026, and is solely responsible for the ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260603:nNDL1q597b:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190630928","title":"IMPACT THERAP-B (07630) to Unveil Phase I/II Trial Results for IMP1734 at 2026 ASCO Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=1190630928","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1190630928?lang=en_us&edition=fundamental","pubTime":"2026-06-01 08:40","pubTimestamp":1780274422,"startTime":"0","endTime":"0","summary":"IMPACT THERAP-B (07630) announced that the latest Phase I/II clinical data for the highly selective PARP1 inhibitor IMP1734 (also known as EIK1003) will be presented in a poster session at the 2026...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199921042","title":"IMPACT Therapeutics highlights IMP1734 Phase 1/2 data at ASCO 2026; monotherapy ORR 14.3%, paclitaxel combo ORR 24.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=1199921042","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1199921042?lang=en_us&edition=fundamental","pubTime":"2026-06-01 08:23","pubTimestamp":1780273420,"startTime":"0","endTime":"0","summary":"IMPACT Therapeutics, Inc. (IMPACT Therapeutics) released updated Phase 1/2 clinical results for its PARP1-selective inhibitor IMP1734 (EIK1003) during the 2026 American Society of Clinical Oncology...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640890009","title":"Impact Therapeutics says PARP1 inhibitor IMP1734 posts 14.3% ORR in Phase 1/2 monotherapy data at ASCO 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2640890009","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640890009?lang=en_us&edition=fundamental","pubTime":"2026-06-01 08:06","pubTimestamp":1780272383,"startTime":"0","endTime":"0","summary":"Impact Therapeutics presented Phase 1/2 data for PARP1 inhibitor IMP1734 at the 2026 ASCO Annual Meeting.Monotherapy showed early signs of durable tumor shrinkage in heavily pretreated patients, with a generally favorable safety profile.A separate cohort combining IMP1734 with weekly paclitaxel showed antitumor activity despite extensive prior taxane use.The combination produced manageable safety in an advanced-line setting, with severe side effects largely consistent with chemotherapy-driven blood toxicities.Data support a strategy to pair a PARP1-selective inhibitor with cytotoxic chemotherapy, an approach the company framed as difficult with older PARP drugs.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Impact Therapeutics Inc. pu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nNDLgDcQN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107678797","title":"Stock Track | Impact Therapeutics-B Soars 15.59% Intraday in Strong Rebound After Post-IPO Profit-Taking","url":"https://stock-news.laohu8.com/highlight/detail?id=1107678797","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1107678797?lang=en_us&edition=fundamental","pubTime":"2026-05-22 11:16","pubTimestamp":1779419803,"startTime":"0","endTime":"0","summary":"Impact Therapeutics-B's stock surged 15.59% intraday, staging a significant rebound in the Hong Kong market. The movement represents a recovery following several sessions of profit-taking pressure...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":3,"totalSize":85,"code":"91000000","status":"200"}]}}